HomeCoronary Artery Disease Scores › Post ACS Secondary Prevention Optimization Tool

Post ACS Secondary Prevention Optimization Tool

  • Left ventricular ejection fraction in percent
  • History of heart failure symptoms or diabetes mellitus
  • Advanced chronic kidney disease with estimated glomerular filtration rate below thirty
  • Current cigarette smoker
  • Diabetes mellitus present
  • Indication for long term oral anticoagulation such as atrial fibrillation
  • High bleeding risk based on clinician judgement or formal bleeding score
  • Patient is currently on dual antiplatelet therapy with aspirin and an oral P2Y12 inhibitor
  • High intensity statin prescribed
  • Most recent low density lipoprotein cholesterol in milligrams per deciliter
  • Nonstatin lipid lowering therapy in use such as ezetimibe or a PCSK9 inhibitor
  • Oral beta blocker prescribed at discharge
  • Renin angiotensin system blocker in use such as angiotensin converting enzyme inhibitor or angiotensin receptor blocker or angiotensin receptor neprilysin inhibitor
  • Mineralocorticoid receptor antagonist prescribed
  • SGLT2 inhibitor or GLP1 receptor agonist prescribed for patients with diabetes or very high cardiovascular risk
  • Cardiac rehabilitation referral completed
  • Vaccinations current including influenza and other guideline directed vaccines
  • Post acute coronary syndrome secondary prevention optimisation tool explanation and clinical context
    This tool is designed to support a structured review of long term therapy in patients who have recently experienced an acute coronary syndrome event. The twenty twenty five acute coronary syndrome guideline emphasises that risk of recurrent events remains elevated for months to years after the index presentation and that sustained secondary prevention is essential to reduce death myocardial infarction stroke and rehospitalisation.

    The calculator organises care into practical domains. Antithrombotic therapy focuses on the presence of combined aspirin and an oral P2Y12 inhibitor for most patients during the first year after acute coronary syndrome with intensity and duration balanced against bleeding risk and the need for chronic oral anticoagulation. Lipid management centres on the use of high intensity statin therapy for all suitable patients with early reassessment of low density lipoprotein cholesterol and timely addition of nonstatin agents in those who do not reach recommended thresholds. Renin angiotensin system blockers and mineralocorticoid receptor antagonists are highlighted for patients with reduced left ventricular ejection fraction or high risk features while oral beta blockers remain important for the prevention of reinfarction and ventricular arrhythmias in the absence of contraindications.

    For patients with diabetes or very high cardiometabolic risk the guideline encourages use of SGLT2 inhibitors and GLP1 receptor agonists with proven cardiovascular benefit as a complement to standard therapies. Cardiac rehabilitation is treated as a core component of care because participation improves exercise capacity quality of life and event free survival and should be arranged using centre based home based or hybrid models according to local availability. Finally the tool reinforces lifestyle modification including complete avoidance of cigarette smoking and optimisation of vaccination status since respiratory infections are a recognised trigger for recurrent coronary events.

    The output of this calculator is not a replacement for clinical judgement or shared decision making. Instead it provides a simple visual summary of which evidence informed domains of post acute coronary syndrome care are already in place and which may warrant further discussion adjustment or initiation in line with contemporary guideline recommendations and individual patient preferences.

    Reference:
    Rao S V O DOnoghue M L Ruel M et al. Twenty twenty five guideline for the management of patients with acute coronary syndromes Journal of the American College of Cardiology twenty twenty five.

Discussion


No discussions yet. Be the first to comment.

Create Note

Notes are stored privately on your device only. No login required. Nothing is uploaded or shared.

My Notes

Report this Tool